Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452956 · ClinicalTrials.gov registry record
Cognitive Impairement In Frontotemporal Dementia
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 997
- Enrollment target
NCT03452956: Completed study, sponsored by University of Pennsylvania.
NCT03452956 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 997 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452956 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 997 participants
- Enrollment target
Study Summary
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). It is hoped the information gathered in this study will help lead to better diagnostics and future treatments.
Primary Outcome
Changes over time in MRI and cognitive testing data.
Interventions
- OTHER None-Observation Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 997 participants |
| Start Date | 2003-07-01 |
| Est. Completion | 2020-07-15 |
What the finished NCT03452956 record still lists
NCT03452956 is an observational study that tracks outcomes without assigning an intervention. The registered 997 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which None-Observation Only is the first listed.
NCT03452956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03452956 about?
NCT03452956 is a clinical study titled "Cognitive Impairement In Frontotemporal Dementia". This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). It is hoped the information gathered in this study will help lead to better diagnostics and future treatmen...
What is the current status of trial NCT03452956?
This trial is currently completed. The enrollment target is 997 participants. The study started on 2003-07-01. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03452956?
The interventions under investigation include: None-Observation Only (OTHER).
Who is sponsoring clinical trial NCT03452956?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI